

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Relugolix with oestradiol and norethindrone acetate for treating uterine fibroids [ID3842]

Final stakeholder list

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Gedeon Richter (relugolix) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Bladder and Bowel Community • Bladder and Bowel UK • British Fibroid Trust • FEmISA • Fibroid Forum UK • Fibroid Network • South Asian Health Foundation • Specialised Healthcare Alliance • Wellbeing of Women • Women's Health Concern <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Royal College of General Practitioners • Royal College of Nursing • Royal College of Obstetricians and Gynaecologists • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • UK Clinical Pharmacy Association <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS Bradford Districts CCG • NHS Brent CCG • NHS England • Welsh Government 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Welsh Health Specialised Services Committee <p><u>Comparator companies</u></p> <ul style="list-style-type: none"> • AstraZeneca (goserelin) • Bayer (combined hormonal contraception, levonorgestrel, norethisterone) • Besins Healthcare (progesterone) • Gedeon Richter (levonorgestrel) • Ipsen (triptorelin) • Lupin Healthcare (combined hormonal contraceptive) • Morningside Healthcare (combined hormonal contraception) • Mylan (combined hormonal contraception)

Final stakeholder list for the single technology appraisal of relugolix with oestradiol and norethindrone acetate for treating uterine fibroids [ID3842]

Issue date: April 2021

© National Institute for Health and Care Excellence 2021. All rights reserved.

1 of 3

Consultees	Commentators (no right to submit or appeal)
	<ul style="list-style-type: none"> • Novo Nordisk (oestradiol and norethisterone acetate) • Organon Pharma (combined hormonal contraceptive) • Pfizer (combined hormonal contraception, medroxyprogesterone, norethisterone) • Takeda UK (leuprorelin) • Wockhardt UK (norethisterone) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Campbell Collaboration Social Welfare Group • Cochrane Menstrual Disorders and Subfertility Group • Genomics England • MRC Clinical Trials Unit • National Institute for Health Research <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> • Public Health Wales • UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

¹ Non-company consultees are invited to submit statements relevant to the group they are representing.